“Extensive-Stage Small Cell Lung Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Extensive-Stage Small Cell Lung Cancer Market.
The Extensive-Stage Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Extensive-Stage Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.
Extensive-Stage Small Cell Lung Cancer companies working in the treatment market are Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical Co, Amgen, Sorrento Therapeutics, BeiGen, and others, are developing therapies for the Extensive-Stage Small Cell Lung Cancer treatment
Emerging Extensive-Stage Small Cell Lung Cancer therapies in the different phases of clinical trials are- RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, and others are expected to have a significant impact on the Extensive-Stage Small Cell Lung Cancer market in the coming years.
In May 2024, Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted approval for IMDELLTRA™ (tarlatamab-dlle) to treat adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum-based chemotherapy. This approval was expedited due to the promising response rate and duration of response (DoR) seen in clinical trials. Ongoing approval for this use may depend on further confirmation of clinical benefits in subsequent confirmatory trials.
In May 2024, Genprex, Inc. has announced that the first patient with extensive-stage small cell lung cancer (ES-SCLC) has begun treatment with a combination of quaratusugene ozeplasmid (Reqorsa) and atezolizumab (Tecentriq) in the phase 1, dose-escalation part of the Acclaim-3 trial (NCT05703971). Acclaim-3 is an open-label, dose-escalation, phase 1/2 study designed to evaluate the clinical response of maintenance therapy using quaratusugene ozeplasmid alongside atezolizumab in patients with ES-SCLC.
Extensive-Stage Small Cell Lung Cancer Overview
Extensive-Stage Small Cell Lung Cancer (ESCLC) is a classification of small cell lung cancer (SCLC), which is a fast-growing type of lung cancer typically associated with heavy smoking. SCLC is divided into two stages: limited stage and extensive stage.
Get a Free Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutic Assessment-
Emerging Extensive-Stage Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:
RP12146: Rhizen Pharmaceuticals
SYHA1807: CSPC ZhongQi Pharmaceutical Technology
BNT411: BioNTech
Bomedemstat: Imago BioSciences
AK104: Akeso
QL1706: Qilu Pharmaceutical Co
Tarlatamab: Amgen
Socazolimab: Sorrento Therapeutics
Tislelizumab: BeiGen
Extensive-Stage Small Cell Lung Cancer Route of Administration
Extensive-Stage Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Extensive-Stage Small Cell Lung Cancer Molecule Type
Extensive-Stage Small Cell Lung Cancer Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment
Extensive-Stage Small Cell Lung Cancer Assessment by Product Type
Extensive-Stage Small Cell Lung Cancer By Stage and Product Type
Extensive-Stage Small Cell Lung Cancer Assessment by Route of Administration
Extensive-Stage Small Cell Lung Cancer By Stage and Route of Administration
Extensive-Stage Small Cell Lung Cancer Assessment by Molecule Type
Extensive-Stage Small Cell Lung Cancer by Stage and Molecule Type
DelveInsight’s Extensive-Stage Small Cell Lung Cancer Report covers around 30+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Extensive-Stage Small Cell Lung Cancer product details are provided in the report. Download the Extensive-Stage Small Cell Lung Cancer pipeline report to learn more about the emerging Extensive-Stage Small Cell Lung Cancer therapies
Extensive-Stage Small Cell Lung Cancer Pipeline Analysis:
The Extensive-Stage Small Cell Lung Cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Extensive-Stage Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer Treatment.
Extensive-Stage Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Extensive-Stage Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Extensive-Stage Small Cell Lung Cancer drugs and therapies
Extensive-Stage Small Cell Lung Cancer Pipeline Market Drivers
The rise in incidence rate of Extensive-Stage Small Cell Lung Cancer (ESCLC), iIncreasing Research and development are some of the important factors that are fueling the Extensive-Stage Small Cell Lung Cancer Market.
Extensive-Stage Small Cell Lung Cancer Pipeline Market Barriers
However, high cost of the treatment, lack of awareness among the people for early detection of cancer and other factors are creating obstacles in the Extensive-Stage Small Cell Lung Cancer Market growth.
Scope of Extensive-Stage Small Cell Lung Cancer Pipeline Drug Insight
Coverage: Global
Key Extensive-Stage Small Cell Lung Cancer Companies: Rhizen Pharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, BioNTech, Imago BioSciences, Akeso, Qilu Pharmaceutical Co, Amgen, Sorrento Therapeutics, BeiGen, and others
Key Extensive-Stage Small Cell Lung Cancer Therapies: RP12146, SYHA1807, BNT411, Bomedemstat, AK104, QL1706, Tarlatamab, Socazolimab, Tislelizumab, and others
Extensive-Stage Small Cell Lung Cancer Therapeutic Assessment: Extensive-Stage Small Cell Lung Cancer current marketed and Extensive-Stage Small Cell Lung Cancer emerging therapies
Extensive-Stage Small Cell Lung Cancer Market Dynamics: Extensive-Stage Small Cell Lung Cancer market drivers and Extensive-Stage Small Cell Lung Cancer market barriers
Request for Sample PDF Report for Extensive-Stage Small Cell Lung Cancer Pipeline Assessment and clinical trials
Table of Contents
1. Extensive-Stage Small Cell Lung Cancer Report Introduction
2. Extensive-Stage Small Cell Lung Cancer Executive Summary
3. Extensive-Stage Small Cell Lung Cancer Overview
4. Extensive-Stage Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment
5. Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics
6. Extensive-Stage Small Cell Lung Cancer Late Stage Products (Phase II/III)
7. Extensive-Stage Small Cell Lung Cancer Mid Stage Products (Phase II)
8. Extensive-Stage Small Cell Lung Cancer Early Stage Products (Phase I)
9. Extensive-Stage Small Cell Lung Cancer Preclinical Stage Products
10. Extensive-Stage Small Cell Lung Cancer Therapeutics Assessment
11. Extensive-Stage Small Cell Lung Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Extensive-Stage Small Cell Lung Cancer Key Companies
14. Extensive-Stage Small Cell Lung Cancer Key Products
15. Extensive-Stage Small Cell Lung Cancer Unmet Needs
16 . Extensive-Stage Small Cell Lung Cancer Market Drivers and Barriers
17. Extensive-Stage Small Cell Lung Cancer Future Perspectives and Conclusion
18. Extensive-Stage Small Cell Lung Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
